NasdaqGS:REGNBiotechs
Regeneron’s Dupixent Win And Telix Deal Add New Layers To Valuation
The European Commission approved Dupixent as the first targeted treatment for moderate to severe chronic spontaneous urticaria in children aged 2 to 11 across the EU.
Regeneron Pharmaceuticals and Telix Pharmaceuticals entered a new radiopharmaceuticals collaboration focused on next generation precision oncology therapies.
Regeneron Pharmaceuticals (NasdaqGS:REGN) is adding fresh pieces to its story in both immunology and oncology. The stock trades around $753.93 and has returned 38.0% over...